Arcutis Biotherapeutics, Inc.
ARQT
$14.73
-$1.43-8.85%
| Weiss Ratings | ARQT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ARQT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ARQT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.79 | |||
| Price History | ARQT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -8.45% | |||
| 30-Day Total Return | 18.89% | |||
| 60-Day Total Return | -3.54% | |||
| 90-Day Total Return | 45.27% | |||
| Year to Date Total Return | 1.17% | |||
| 1-Year Total Return | 29.89% | |||
| 2-Year Total Return | 32.82% | |||
| 3-Year Total Return | -29.62% | |||
| 5-Year Total Return | -48.04% | |||
| 52-Week High % Change | -17.01% | |||
| 52-Week Low % Change | 110.73% | |||
| Price | ARQT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $17.75 | |||
| 52-Week Low Price | $6.99 | |||
| 52-Week Low Price (Date) | Jun 10, 2024 | |||
| 52-Week High Price (Date) | Mar 25, 2025 | |||
| Valuation | ARQT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.75B | |||
| Enterprise Value | 1.63B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.16 | |||
| Earnings Per Share Growth | -70.23% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 9.36 | |||
| Price/Book (Q) | 11.02 | |||
| Enterprise Value/Revenue (TTM) | 8.29 | |||
| Price | $14.73 | |||
| Enterprise Value/EBITDA (TTM) | -12.96 | |||
| Enterprise Value/EBIT | -12.70 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | ARQT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 124.92M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ARQT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 805 418 5006 | |||
| Address | 3027 Townsgate Road Westlake Village, CA 91361 | |||
| Website | www.arcutis.com | |||
| Country | United States | |||
| Year Founded | 2016 | |||
| Profitability | ARQT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -65.32% | |||
| Profit Margin | -71.25% | |||
| Management Effectiveness | ARQT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -23.25% | |||
| Return on Equity | -- | |||
| Income Statement | ARQT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 166.54M | |||
| Total Revenue (TTM) | 196.54M | |||
| Revenue Per Share | $1.57 | |||
| Gross Profit (TTM) | 177.41M | |||
| EBITDA (TTM) | -125.80M | |||
| EBIT (TTM) | -128.40M | |||
| Net Income (TTM) | -140.04M | |||
| Net Income Avl. to Common (TTM) | -140.04M | |||
| Total Revenue Growth (Q YOY) | 427.58% | |||
| Earnings Growth (Q YOY) | 83.72% | |||
| EPS Diluted (TTM) | -1.16 | |||
| EPS Diluted Growth (Q YOY) | 87.93% | |||
| Balance Sheet | ARQT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 227.96M | |||
| Cash Per Share (Q) | $1.82 | |||
| Total Current Assets (Q) | 335.82M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 157.54M | |||
| Current Ratio (Q) | 4.145 | |||
| Book Value Per Share (Q) | $1.34 | |||
| Total Assets (Q) | 348.89M | |||
| Total Current Liabilities (Q) | 81.01M | |||
| Total Debt (Q) | 110.59M | |||
| Total Liabilities (Q) | 191.35M | |||
| Total Common Equity (Q) | 157.54M | |||
| Cash Flow | ARQT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 28.82M | |||
| Cash from Financing (TTM) | 66.20M | |||
| Net Change in Cash (TTM) | -17.37M | |||
| Levered Free Cash Flow (TTM) | -72.62M | |||
| Cash from Operations (TTM) | -112.16M | |||
